SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$2.91 -0.53%

-$0.02 today

Market cap
$262.16M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 1.75M

Average 0.76M

Returns on capital

SAB Biotherapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

8.8%

avg 20.0%

ROIC

-30.0%

avg -44.3%

ROA

7.7%

avg -27.4%

Analysis

ROE is currently the strongest return metric at 8.8% versus its period average of 20.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Samuel J. Reich

CEO & DirectorUSD 846.46K514.80M5.28%

Alexandra Kropotova

Executive Vice President & Chief Medical OfficerUSD 832.25K5341.85K0.05%

Eddie Joe Sullivan

Co-Founder, President & DirectorUSD 746.5K593.00M3.30%

Lucy To

Executive Vice President & Chief Financial OfficerUSD 684.03K402.40M2.64%

Christoph Bausch

Executive Vice President & Chief Operating OfficerUSD 609K55——

Angie Parizek

Senior Vice President of Clinical Operations————

Hua Wu

Senior Vice President of Product Development——4.65K<0.01%

Carlos N. Carillo

Senior Vice President of Regulatory Affairs——17.68K0.02%

Catherine DeRose

Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 18, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
-13.5% (5yr)6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Forward estimates point to Net Income at -13.5% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does SAB Biotherapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SABS's management, answered from reported figures.

Who manages SABS?

SAB Biotherapeutics, Inc. (SABS) lists 9 active executives. The top listed executive is Samuel J. Reich, CEO & Director.

Are SABS insiders buying or selling?

Recent insider activity shows net buying of $377.21M.